MCID: FLL037
MIFTS: 67

Follicular Lymphoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma

MalaCards integrated aliases for Follicular Lymphoma:

Name: Follicular Lymphoma 12 74 52 36 29 6 15 37 32
Lymphoma, Follicular 52 43 71
Lymphoma Follicular 54

Classifications:



Summaries for Follicular Lymphoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 545 Definition Follicular lymphoma is a form of non-Hodgkin lymphoma (see this term) characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved. Epidemiology Prevalence of follicular lymphoma is estimated at about 1/3,000. Clinical description The median age at diagnosis is 60-65 years. The disease is extremely rare in children. Follicular lymphoma is located primarily in the lymph nodes , but can also involve the spleen, bone marrow, peripheral blood and Waldeyer's ring. The skin and central nervous system are affected in rare cases. Symptoms appear at an advanced stage of the disease and can include fever, night sweats and weight loss. At diagnosis, patients usually present with adenopathy and, in 50% of cases, splenomegaly. Etiology In 85% of cases, follicular lymphomas are associated with a translocation t(14;18) (q32;q21), which activates the BCL2 gene encoding the BCL2 protein that is essential for some apoptosis processes. Diagnostic methods Diagnosis is based on histological analysis of the adenopathy, a complete blood count, measurement of lactate dehydrogenase (LDH) and biopsy analysis of a lymph node. Examination using imagery (particularly a chest radiograph) is required. The observation of the translocation t(14;18) by polymerase chain reaction (PCR), in addition to suggested histological results, confirms the diagnosis. Differential diagnosis Differential diagnoses include chronic lymphocytic B cell leukemia, diffuse large B cell lymphoma, mantle cell lymphoma and MALT lymphoma (see these terms). Management and treatment If the lymphoma is localized it should be treated by radiotherapy. In the case of advanced stage lymphoma, chemotherapy with immuno-chemotherapy should be offered (rituximab combined with CHOP). In cases of chemosensitive relapse, treatment can be intensified. Prognosis The survival rate at five years is 80-90% and medial survival is approximately 10-12 years. Visit the Orphanet disease page for more resources.

MalaCards based summary : Follicular Lymphoma, also known as lymphoma, follicular, is related to follicular lymphoma 1 and lymphoma aids related. An important gene associated with Follicular Lymphoma is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Notch Signaling Pathway (WikiPathways) and DNA Damage Response. The drugs Entecavir and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are fever and weight loss

Disease Ontology : 12 A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has material basis in follicle center B-cells (centrocytes and centroblasts).

KEGG : 36 Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement. The genetic hallmark of FL, the translocation t(14;18)(q32;q21), results in the constitutive overexpression of the bcl 2 protein, which impairs the normal germinal centre apoptotic programme. Inactivating mutations of MLL2 are found in >80% of FL and interfere with the ability of MLL2 to activate gene transcription through H3K4 methylation. Mutations of other histone modifiers (CREBBP, EZH2, MEF2B, and EP300) are found in ;33%, 27%, 15%, and 9% of FL, respectively.

Wikipedia : 74 Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as... more...

Related Diseases for Follicular Lymphoma

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 517)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 1 35.3 FL1 BCL6 BCL2 BCL10
2 lymphoma aids related 32.4 MYC BCL6
3 nodal marginal zone b-cell lymphoma 32.4 BCL6 BCL2
4 lymphoma 32.4 ZC3H12D MYC MME KDSR CCND1 BCL6
5 lymphoblastic lymphoma 32.3 MYC MME BCL6
6 diffuse large b-cell lymphoma of the central nervous system 32.2 MYC BCL2
7 plasmablastic lymphoma 32.1 MYC BCL6
8 primary central nervous system lymphoma 31.9 BCL6 BCL2
9 burkitt lymphoma 31.9 MYC MME MIR155 CCND1 BCL6 BCL2
10 mantle cell lymphoma 31.9 MYC MME MIR155 CCND1 BCL6 BCL2
11 marginal zone b-cell lymphoma 31.7 MME CCND1 BCL6 BCL10
12 primary mediastinal large b-cell lymphoma 31.6 BCL6 BCL2
13 intravascular large b-cell lymphoma 31.6 MME BCL6 BCL2
14 t-cell/histiocyte rich large b cell lymphoma 31.5 MME BCL6
15 lymphosarcoma 31.4 BCL6 BCL2
16 b-cell lymphoma 31.4 MYC MME MIR181A1 MIR155 CCND1 BCL6
17 cll/sll 31.2 MME CCND1 BCL6
18 reticulosarcoma 31.2 MYC BCL6 BCL2
19 composite lymphoma 31.1 MME BCL6
20 myeloma, multiple 31.1 MYC MME CCND1 BCL6 BCL2
21 lymphoma, mucosa-associated lymphoid type 31.1 MYC MME CCND1 BCL6 BCL2 BCL10
22 nodular lymphocyte predominant hodgkin lymphoma 31.0 CCND1 BCL6
23 prostate lymphoma 30.9 MME BCL6
24 adult lymphoma 30.8 MYC MME BCL6
25 breast lymphoma 30.8 MME BCL6
26 gastrointestinal lymphoma 30.7 MME CCND1 BCL6
27 peripheral t-cell lymphoma 30.7 MME CCND1 BCL6
28 ovarian lymphoma 30.6 MME BCL6
29 plasma cell neoplasm 30.6 MYC MME CCND1 BCL6
30 bone lymphoma 30.6 MME BCL6
31 gray zone lymphoma 30.5 MME BCL6
32 t-cell lymphoblastic leukemia/lymphoma 30.5 MYC MIR106A CCND1 BCL2
33 thyroid lymphoma 30.4 MME BCL6
34 leukemia, chronic lymphocytic 30.4 MYC MME MIR338 MIR181A1 MIR155 CCND1
35 plasmacytoma 30.3 MYC CCND1 AICDA
36 ductal carcinoma in situ 30.3 MYC MME CCND1
37 mature b-cell neoplasm 30.2 MYC MME MIR155 CCND1 BCL6 AICDA
38 leukemia, acute lymphoblastic 30.2 MYC MME MIR210 MIR155 MIR149 BCL6
39 primary mediastinal b-cell lymphoma 29.9 ZC3H12D MIR181A1 MIR155 BCL6 AICDA
40 lymphoma, non-hodgkin, familial 29.9 MYC MME MIR338 MIR181A1 MIR155 MIR149
41 in situ carcinoma 29.8 MYC MIR181A1 MIR139 CCND1
42 cholangiocarcinoma 29.6 MME MIR320A MIR301A CCND1
43 acute promyelocytic leukemia 29.5 MYC MIR210 MIR181A1 CCND1 BCL6 BCL2
44 diffuse large b-cell lymphoma 29.5 ZC3H12D MYC MME MIR320A MIR210 MIR181A1
45 central nervous system disease 29.3 MIR338 MIR210 MIR181A1 MIR155
46 prostate disease 29.2 MIR330 MIR181A1 MIR149 MIR139
47 lung cancer susceptibility 3 28.9 MYC MIR338 MIR330 MIR149 MIR139 CCND1
48 glioblastoma multiforme 28.8 MYC MIR210 MIR155 MIR149 MIR139 CCND1
49 leukemia, acute myeloid 28.7 MYC MME MIR338 MIR330 MIR320A MIR210
50 squamous cell carcinoma, head and neck 28.7 MYC MIR210 MIR181A1 MIR155 MIR149 MIR139

Graphical network of the top 20 diseases related to Follicular Lymphoma:



Diseases related to Follicular Lymphoma

Symptoms & Phenotypes for Follicular Lymphoma

Human phenotypes related to Follicular Lymphoma:

31 (show all 12)
# Description HPO Frequency HPO Source Accession
1 fever 31 hallmark (90%) HP:0001945
2 weight loss 31 hallmark (90%) HP:0001824
3 lymphoma 31 hallmark (90%) HP:0002665
4 mediastinal lymphadenopathy 31 hallmark (90%) HP:0100721
5 night sweats 31 hallmark (90%) HP:0030166
6 splenomegaly 31 frequent (33%) HP:0001744
7 fatigue 31 frequent (33%) HP:0012378
8 lymphedema 31 occasional (7.5%) HP:0001004
9 meningitis 31 occasional (7.5%) HP:0001287
10 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585
11 pleural effusion 31 occasional (7.5%) HP:0002202
12 skin nodule 31 occasional (7.5%) HP:0200036

Drugs & Therapeutics for Follicular Lymphoma

Drugs for Follicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 444)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
4
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
5
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
6
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
7
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
8 Orange Approved Phase 3
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
12
Ribavirin Approved Phase 3 36791-04-5 37542
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
15
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
16
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
17
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
18
Teniposide Approved Phase 3 29767-20-2 34698
19
Ifosfamide Approved Phase 3 3778-73-2 3690
20
leucovorin Approved Phase 3 58-05-9 6006 143
21
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
22
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
23
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Dalteparin Approved Phase 3 9005-49-6
26
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
27
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
29
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
30
Ofloxacin Approved Phase 3 82419-36-1 4583
31
Idarubicin Approved Phase 3 58957-92-9 42890
32
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
33
Tazobactam Approved Phase 3 89786-04-9 123630
34
Vancomycin Approved Phase 3 1404-90-6 14969 441141
35
Piperacillin Approved Phase 3 66258-76-2 43672
36
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
37
Captopril Approved Phase 3 62571-86-2 44093
38
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
41
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
42
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
43
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
44
Idelalisib Approved Phase 3 870281-82-6
45
Pixantrone Approved, Investigational Phase 3 144510-96-3
46
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
47
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
48
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
49
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
50
Ethinyl Estradiol Approved Phase 3 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 1165)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
4 A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma Recruiting NCT03817853 Phase 4 Obinutuzumab;Bendamustine;Cyclophosphamide;Doxorubicin;Prednisone/Prednisolone/Methylprednisolone;Vincristine
5 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
6 Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial Unknown status NCT00028691 Phase 3 chlorambucil
7 Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
8 Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
9 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
10 MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA Unknown status NCT00435955 Phase 3 Rituximab
11 Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
12 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
13 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
14 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
15 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
16 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
17 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
18 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
19 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
20 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
21 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
22 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
23 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
24 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
25 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
26 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
27 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
28 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
29 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
30 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
31 FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden Completed NCT00136552 Phase 3 rituximab
32 A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen Completed NCT02569996 Phase 3 Rituximab
33 A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma Completed NCT02162771 Phase 3 Cyclophosphamide;Vincristine;Prednisone
34 Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy Completed NCT00140582 Phase 3 Rituximab
35 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Completed NCT02213263 Phase 3
36 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
37 A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
38 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
39 Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden Completed NCT00696735 Phase 3
40 Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial Completed NCT00185393 Phase 3
41 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
42 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
43 Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy Completed NCT00003204 Phase 3 cyclophosphamide;fludarabine phosphate;vincristine sulfate;prednisone
44 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
45 Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma Completed NCT00577993 Phase 3 Fludarabine;Novantrone;Decadron;Rituximab;Interferon;Doxorubicin;Vincristine;Bleomycin;Cyclophosphamide;Etoposide;Cisplatin;Ara-C;Methyl-Prednisolone;Procarbazine;Prednisone
46 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
47 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
48 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
49 A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
50 Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial Completed NCT00227695 Phase 3

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ibritumomab tiuxetan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, follicular

Genetic Tests for Follicular Lymphoma

Genetic tests related to Follicular Lymphoma:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 29

Anatomical Context for Follicular Lymphoma

MalaCards organs/tissues related to Follicular Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Breast

Publications for Follicular Lymphoma

Articles related to Follicular Lymphoma:

(show top 50) (show all 6222)
# Title Authors PMID Year
1
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 61 46
18537969 2008
2
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
3
Prominent Dutcher body formation in a case of follicular lymphoma with BCL6 gene rearrangement and intact BCL2 gene. 61 54
20069653 2010
4
Mechanisms of chromosomal rearrangement in the human genome. 54 61
20158866 2010
5
Rituximab inhibits B-cell receptor signaling. 54 61
19965664 2010
6
Cyclin D1 positive follicular lymphoma. 61 54
19734488 2009
7
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. 54 61
19519691 2009
8
PDTC enables type I TRAIL signaling in type II follicular lymphoma cells. 54 61
18977530 2009
9
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. 61 54
19414675 2009
10
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. 61 54
19321861 2009
11
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. 61 54
19363496 2009
12
Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma. 61 54
19537891 2009
13
Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch. 61 54
19351371 2009
14
The expression of activation induced cytidine deaminase in follicular lymphoma is independent of prognosis and stage. 61 54
19309412 2009
15
Follicular lymphoma of the thyroid gland. 54 61
18830125 2009
16
Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. 54 61
19207947 2009
17
Structure of the wild-type human BCL6 POZ domain. 61 54
19052359 2008
18
Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. 61 54
18945749 2008
19
Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. 54 61
18925696 2008
20
A novel fusion 5'AFF3/3'BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma. 54 61
18622426 2008
21
BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation. 54 61
18500267 2008
22
The prevention of spontaneous apoptosis of follicular lymphoma B cells by a follicular dendritic cell line: involvement of caspase-3, caspase-8 and c-FLIP. 61 54
18556415 2008
23
Treatment of follicular non-Hodgkin's lymphoma: the old and the new. 61 54
18760706 2008
24
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. 61 54
18427151 2008
25
Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. 61 54
18089500 2008
26
Molecular frequency of BCL2/JH t(14; 18) using PCR among Lebanese patients with follicular lymphoma: another piece of the geographical map revealed. 61 54
17149654 2007
27
Derivative (3)t(3;18)(q27;q21)t(18;16)(q21;?) involving the BCL2 and BCL6 genes in follicular lymphoma with t(3;14;18)(q27;q32;q21). 61 54
17981218 2007
28
High frequency of BCL2 translocation in Thai patients with follicular lymphomas. 61 54
18055344 2007
29
BNIP3 expression in follicular lymphoma. 54 61
17394490 2007
30
Role of the chromobox protein CBX7 in lymphomagenesis. 54 61
17374722 2007
31
Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. 61 54
17295647 2007
32
MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. 54 61
17296585 2007
33
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. 54 61
17256834 2007
34
A novel t(2;3)(p11;q27) in a case of follicular lymphoma. 61 54
17175383 2007
35
BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. 54 61
17150023 2007
36
Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. 61 54
17088997 2006
37
Pathogenetic and clinical implications of non-immunoglobulin ; BCL6 translocations in B-cell non-Hodgkin's lymphoma. 61 54
17142954 2006
38
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 61 54
16983704 2006
39
[BCL-XL expression and mutation in non-Hodgkin's lymphoma]. 54 61
17096886 2006
40
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. 54 61
17026765 2006
41
Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. 54 61
16939500 2006
42
The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function. 54 61
16777355 2006
43
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 54 61
16847683 2006
44
BCL2 gene abnormalities define distinct clinical subsets of follicular lymphoma. 61 54
16918969 2006
45
Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. 61 54
16893519 2006
46
BCR-bound antigen is targeted to exosomes in human follicular lymphoma B-cells. 54 61
16677129 2006
47
A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. 54 61
16772123 2006
48
Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma. 54 61
16125304 2006
49
Therapeutic lymphoma vaccines: importance of T-cell immunity. 61 54
16827622 2006
50
The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. 61 54
16769579 2006

Variations for Follicular Lymphoma

ClinVar genetic disease variations for Follicular Lymphoma:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BCL10 NM_003921.5(BCL10):c.427_428dup (p.Glu145fs)duplication Pathogenic 6253 rs587776632 1:85733583-85733584 1:85267900-85267901
2 BCL10 NM_003921.5(BCL10):c.231dup (p.Gly78fs)duplication Pathogenic 6254 rs587776633 1:85736415-85736416 1:85270732-85270733
3 BCL10 NM_003921.5(BCL10):c.525_541del (p.Val176fs)deletion Pathogenic 6255 rs587776634 1:85733471-85733487 1:85267788-85267804
4 BCL10 NM_003921.5(BCL10):c.410del (p.Asn137fs)deletion Pathogenic 6256 rs587776635 1:85733602-85733602 1:85267919-85267919
5 BCL10 NM_003921.5(BCL10):c.398dup (p.Ser134fs)duplication Pathogenic 6257 rs587776636 1:85733613-85733614 1:85267930-85267931
6 BCL10 NM_003921.5(BCL10):c.629_631AAG[2] (p.Glu212del)short repeat Pathogenic 6258 rs587776637 1:85733375-85733377 1:85267692-85267694

Cosmic variations for Follicular Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93183630 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 17:7674220-7674220 4

Copy number variations for Follicular Lymphoma from CNVD:

7 (show top 50) (show all 76)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13361 1 1 12700000 Copy number Follicular lymphoma
2 13749 1 1 27800000 Loss Follicular lymphoma
3 15761 1 119415209 120497765 Amplification NOTCH2 Follicular lymphoma
4 17512 1 143222462 153482569 Copy number ADAM15 Follicular lymphoma
5 17513 1 143222462 153482569 Copy number BCL9 Follicular lymphoma
6 17514 1 143222462 153482569 Copy number IL6R Follicular lymphoma
7 17515 1 143222462 153482569 Copy number MCL1 Follicular lymphoma
8 17516 1 143222462 153482569 Copy number PIAS3 Follicular lymphoma
9 17517 1 143222462 153482569 Copy number TNFAIP8L2 Follicular lymphoma
10 20608 1 153300000 154800000 Gain Follicular lymphoma
11 21393 1 158419998 161795584 Copy number DDR2 Follicular lymphoma
12 21394 1 158419998 161795584 Copy number PEX19 Follicular lymphoma
13 21395 1 158419998 161795584 Copy number UHMK1 Follicular lymphoma
14 25231 1 185800000 214500000 Gain Follicular lymphoma
15 54389 11 43400000 52900000 Gain Follicular lymphoma
16 61270 11 97200000 110400000 Gain Follicular lymphoma
17 65472 12 18053500 31175376 Amplification KRAS Follicular lymphoma
18 65473 12 18053500 31175376 Amplification PIK3C2G Follicular lymphoma
19 65474 12 18053500 31175376 Amplification RASSF8 Follicular lymphoma
20 65475 12 18053500 31175376 Amplification RERGL Follicular lymphoma
21 65476 12 18053500 31175376 Amplification SSPN Follicular lymphoma
22 67780 12 44600000 56300000 Gain Follicular lymphoma
23 69831 12 56316396 72147648 Copy number CDK4 Follicular lymphoma
24 69832 12 56316396 72147648 Copy number DYRK2 Follicular lymphoma
25 69833 12 56316396 72147648 Copy number FRS2 Follicular lymphoma
26 69834 12 56316396 72147648 Copy number IL22 Follicular lymphoma
27 69835 12 56316396 72147648 Copy number MDM2 Follicular lymphoma
28 69836 12 56316396 72147648 Copy number OS9 Follicular lymphoma
29 69837 12 56316396 72147648 Copy number RAB21 Follicular lymphoma
30 69838 12 56316396 72147648 Copy number RAP1B Follicular lymphoma
31 69839 12 56316396 72147648 Copy number RASSF3 Follicular lymphoma
32 69840 12 56316396 72147648 Copy number TBK1 Follicular lymphoma
33 69841 12 56316396 72147648 Copy number TSPAN31 Follicular lymphoma
34 69842 12 56316396 72147648 Copy number WIF1 Follicular lymphoma
35 69843 12 56316396 72147648 Copy number YEATS4 Follicular lymphoma
36 71140 12 67700000 71500000 Gain Follicular lymphoma
37 74580 13 109100000 114142980 Loss Follicular lymphoma
38 79541 13 73300000 79000000 Gain Follicular lymphoma
39 88260 14 88900000 106368585 Loss Follicular lymphoma
40 88262 14 88900000 106368585 Translocation Follicular lymphoma
41 92360 15 40100000 102531392 Loss Follicular lymphoma
42 97239 16 1 16700000 Gain Follicular lymphoma
43 106783 17 1 22200000 Deletion Follicular lymphoma
44 106829 17 1 24000000 Loss Follicular lymphoma
45 107553 17 15900000 22200000 Gain Follicular lymphoma
46 111280 17 35400000 47600000 Gain Follicular lymphoma
47 118113 17 7571720 7590868 Mutation P53 Follicular lymphoma
48 119191 18 1 59800000 Gain Follicular lymphoma
49 120855 18 33040900 33600413 Amplification BRUNOL4 Follicular lymphoma
50 121287 18 41800000 59800000 Translocation Follicular lymphoma

Expression for Follicular Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Follicular Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 56)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCRLA Fc receptor-like A Intestine + 6.40 0.000
2 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 Intestine + 5.98 0.000
3 VPREB3 pre-B lymphocyte 3 Intestine + 5.82 0.000
4 STAG3 stromal antigen 3 Intestine + 5.61 0.000
5 SNX22 sorting nexin 22 Intestine + 5.59 0.000
6 NLRP4 NLR family, pyrin domain containing 4 Intestine + 4.89 0.004
7 LTF lactotransferrin Intestine + 4.72 0.001
8 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Intestine + 4.70 0.000
9 AIM2 absent in melanoma 2 Intestine + 4.66 0.000
10 P2RX5 purinergic receptor P2X, ligand gated ion channel, 5 Intestine + 4.54 0.000
11 BFSP2 beaded filament structural protein 2, phakinin Intestine + 4.33 0.000
12 DOK7 docking protein 7 Intestine + 4.29 0.000
13 KLHL14 kelch-like family member 14 Intestine + 4.26 0.000
14 GPR18 G protein-coupled receptor 18 Intestine + 4.26 0.000
15 PAX5 paired box 5 Intestine + 4.21 0.000
16 CNR1 cannabinoid receptor 1 (brain) Intestine + 4.15 0.001
17 PMCH pro-melanin-concentrating hormone Intestine + 4.09 0.000
18 AFF3 AF4/FMR2 family, member 3 Intestine + 4.02 0.000
19 MMP12 matrix metallopeptidase 12 Intestine + 3.94 0.001
20 LOC613266 uncharacterized LOC613266 Intestine + 3.92 0.000
21 C17orf99 chromosome 17 open reading frame 99 Intestine + 3.88 0.003
22 PCDHGB3 protocadherin gamma subfamily B, 3 Intestine + 3.82 0.002
23 TMEM156 transmembrane protein 156 Intestine + 3.81 0.000
24 FCRL2 Fc receptor-like 2 Intestine + 3.76 0.001
25 SCIMP SLP adaptor and CSK interacting membrane protein Intestine + 3.75 0.000
26 CCL17 chemokine (C-C motif) ligand 17 Intestine + 3.73 0.004
27 VNN2 vanin 2 Intestine + 3.71 0.000
28 OR13A1 olfactory receptor, family 13, subfamily A, member 1 Intestine + 3.59 0.001
29 PCDHGB2 protocadherin gamma subfamily B, 2 Intestine + 3.53 0.001
30 CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11 Intestine - 3.53 0.015
31 APOBEC2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 Intestine - 3.51 0.003
32 KIAA1549L KIAA1549-like Intestine + 3.45 0.003
33 TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) Intestine + 3.41 0.005
34 AFF2 AF4/FMR2 family, member 2 Intestine + 3.35 0.006
35 CD37 CD37 molecule Intestine + 3.24 0.000
36 IL22RA2 interleukin 22 receptor, alpha 2 Intestine + 3.22 0.012
37 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Intestine + 3.22 0.001
38 ARHGAP24 Rho GTPase activating protein 24 Intestine + 3.21 0.001
39 PLEKHG7 pleckstrin homology domain containing, family G (with RhoGef domain) member 7 Intestine + 3.20 0.000
40 CAPN14 calpain 14 Intestine + 3.20 0.002
41 SPANXN3 SPANX family, member N3 Intestine - 3.18 0.002
42 TMEM155 transmembrane protein 155 Intestine + 3.16 0.002
43 RPS16P5 ribosomal protein S16 pseudogene 5 Intestine + 3.15 0.000
44 SLC7A10 solute carrier family 7 (neutral amino acid transporter light chain, asc system), member 10 Intestine + 3.15 0.002
45 SLC5A12 solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 Intestine - 3.13 0.000
46 PCDH11Y protocadherin 11 Y-linked Intestine + 3.13 0.001
47 BEND4 BEN domain containing 4 Intestine + 3.13 0.001
48 PCDHGA5 protocadherin gamma subfamily A, 5 Intestine + 3.12 0.006
49 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 Intestine + 3.11 0.008
50 PDCD1 programmed cell death 1 Intestine + 3.09 0.001
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for Follicular Lymphoma

GO Terms for Follicular Lymphoma

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR338 MIR320A MIR301A MIR210 MIR181A1 MIR155

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.76 MYC MIR338 MIR181A1 MIR155
2 cytokine-mediated signaling pathway GO:0019221 9.73 MYC CCND1 BCL6 BCL2
3 regulation of apoptotic process GO:0042981 9.71 MIR155 BCL6 BCL2 BCL10
4 B cell differentiation GO:0030183 9.54 BCL6 BCL2 AICDA
5 negative regulation of cell migration GO:0030336 9.46 MIR338 MIR320A MIR149 BCL2
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.43 MIR320A MIR155 MIR149
7 re-entry into mitotic cell cycle GO:0000320 9.32 MYC CCND1
8 gene silencing by miRNA GO:0035195 9.32 MIR338 MIR330 MIR320A MIR301A MIR210 MIR181A1
9 miRNA mediated inhibition of translation GO:0035278 9.26 MIR210 MIR181A1 MIR155 MIR106A

Molecular functions related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR338 MIR330 MIR320A MIR301A MIR210 MIR181A1

Sources for Follicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....